SCHEMBL5539795

SCHEMBL5539795

CC(=O)N1CCN(Cc2c(C)cc(C)cc2C)CC1

nearest known ligand 0.53

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 3/20 0.53
EPHX2 P34913 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.47
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
ATM Q13315 1/20 0.44
RORC P51449 1/20 0.44
PIK3CD O00329 1/20 0.43
ALDH1A1 P00352 3/20 0.43
GALR3 O60755 2/20 0.41
NR2F2 P24468 2/20 0.41
KDM4E B2RXH2 1/20 0.41
GRIN2B Q13224 1/20 0.41
PARP1 P09874 1/20 0.41
PARP2 Q9UGN5 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5539792 0.85 EPHX2 (0.48) HRH3EPHX2L3MBTL1MEN1KMT2A
SCHEMBL9987629 0.80 ALDH1A1 (0.48) EPHX2MEN1KMT2AATMALDH1A1
SCHEMBL5537920 0.80 GRIN2B (0.63) HRH3MEN1KMT2AALDH1A1GRIN2B
SCHEMBL11891933 0.77 HRH3 (0.52) HRH3EPHX2ALDH1A1KDM4E
SCHEMBL11154999 0.75 HRH3 (0.59) HRH3L3MBTL1MEN1KMT2AATM
SCHEMBL10701848 0.75 HRH3 (0.46) HRH3EPHX2MEN1KMT2AALDH1A1
SCHEMBL6295492 0.75 HRH3 (0.55) HRH3L3MBTL1MEN1KMT2AATM
SCHEMBL17896797 0.75 HRH3 (0.55) HRH3MEN1KMT2AATMRORC
SCHEMBL5542065 0.75 EPHX2 (0.44) HRH3EPHX2MEN1KMT2AALDH1A1
SCHEMBL10702796 0.75 EPHX2 (0.44) HRH3EPHX2L3MBTL1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 HRH3 420/4885EPHX2 3662/4885L3MBTL1 1931/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.